Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
45.04
-1.48 (-3.18%)
Nov 20, 2024, 4:00 PM EST - Market closed
Apogee Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Selling, General & Admin | 41.55 | 24.58 | 3.21 |
| Research & Development | 136.59 | 68.42 | 30.31 |
| Operating Expenses | 178.14 | 93 | 33.52 |
| Operating Income | -178.14 | -93 | -33.52 |
| Interest & Investment Income | 31.48 | 9.02 | 0.1 |
| Other Non Operating Income (Expenses) | - | - | -9.98 |
| Pretax Income | -146.66 | -83.99 | -43.4 |
| Net Income | -146.66 | -83.99 | -43.4 |
| Net Income to Common | -146.66 | -83.99 | -43.4 |
| Shares Outstanding (Basic) | 53 | 25 | 2 |
| Shares Outstanding (Diluted) | 53 | 25 | 2 |
| Shares Change (YoY) | 272.26% | 915.57% | - |
| EPS (Basic) | -2.77 | -3.36 | -17.63 |
| EPS (Diluted) | -2.77 | -3.36 | -17.63 |
| Free Cash Flow | -134.53 | -74.93 | -17.92 |
| Free Cash Flow Per Share | -2.54 | -3.00 | -7.28 |
| EBIT | -178.14 | -93 | -33.52 |
Source: S&P Capital IQ. Standard template.
Financial Sources.